CCA
BOLD

Catalyst Capital Advisors’s Audentes Therapeutics, Inc BOLD Stock Holding History

Catalyst Capital Advisors’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-230
Closed -$4K – 557
2016
Q3 		$4K Buy
+230
New +$3.49K ﹤0.01% 392

Other funds holding BOLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Catalyst Capital Advisors's BOLD Position: Q4 2016 in Review

Catalyst Capital Advisors sold out of Audentes Therapeutics, Inc (BOLD) in Q4 2016, closing a stake of 230 shares — an estimated $4K sold.

Catalyst Capital Advisors first reported a position in BOLD in Q3 2016 and held it in 1 quarter. The position peaked at $4K in Q3 2016. 57 funds tracked by Wall St. Rank hold BOLD as of Q4 2016.

  • Catalyst Capital Advisors reported no remaining Audentes Therapeutics, Inc position as of Q4 2016 after selling out during the quarter.
  • Catalyst Capital Advisors sold 230 Audentes Therapeutics, Inc shares in Q4 2016, an estimated $4K.
  • Catalyst Capital Advisors first reported a position in Audentes Therapeutics, Inc in Q3 2016 and held it in 1 quarter.
  • Catalyst Capital Advisors's Audentes Therapeutics, Inc position peaked at $4K in Q3 2016.
  • 57 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q4 2016.

Based on Catalyst Capital Advisors's 13F filing for Q4 2016, filed 8 Feb 2017.